CDKL5 Deficiency Disorder Clinical Trial Landscape
Data updated: May 20, 2026
5 clinical trials tracked since 2008
CDKL5 Deficiency Disorder is being studied across 5 clinical trials registered since 2008, with 2 programs currently active. The competitive pipeline includes 2 active Phase 3 trials, 0 active Phase 2 trials, and 0 active Phase 1 trials. Top industry sponsors include Zogenix, Inc., Immedica Pharma AB.
2 active
/
5 total (since 2008)
0
Phase 1 Active
0 total
0
Phase 2 Active
2 total
2
Phase 3 Active
3 total
0
Phase 4 Active
0 total
Top Industry Sponsors
Sorted by active Active Done Failed
Zogenix, Inc. 1 0 0
Immedica Pharma AB 1 0 0
Featured Phase 3 Trials
NCT05064878 ACTIVE NOT RECRUITING
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
Zogenix, Inc. n=87
NCT03572933 COMPLETED
Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder
Marinus Pharmaceuticals n=101
NCT05249556 NOT YET RECRUITING
Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old
Immedica Pharma AB n=20
CDKL5 Deficiency Disorder — Trials Started by Year (last 10 years)
2016 0
2017 0
2018 2
2019 1
2020 0
2021 0
2022 1
2023 0
2024 0
2025 0
2026 1
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Zogenix, Inc. 1
Immedica Pharma AB 1
Marinus Pharmaceuticals 1
Takeda 1
Active Trials by Phase
Phase 3 2
Enrollment Size Distribution
1-50 3
51-200 2
201-500 0
501-1k 0
1k+ 0
All Industry Sponsors
Sorted by active Active Done Failed
Zogenix, Inc. 1 0 0
Immedica Pharma AB 1 0 0
NCT05064878 ACTIVE NOT RECRUITING
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
Zogenix, Inc. n=87
NCT05249556 NOT YET RECRUITING
Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old
Immedica Pharma AB n=20
NCT03572933 COMPLETED
Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder
Marinus Pharmaceuticals n=101
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only